The apxIIC gene of Actinobacillus pleuropneumoniae serotype 7 was inactivated by homologous recombination using a sucrose counter-selectable marker system, resulting in a mutant strain that had no antibiotic resistance marker and expressed an inactivated ApxII toxin. The safety and immunogenicity of the mutant were evaluated in mice. The mutant strain caused no adverse effects in mice at doses up to 2 × 109 CFU via the intraperitoneal route while the parental strain induced total mortality at a dose of 2 × 107 CFU. Mice vaccinated intraperitoneally with the mutant strain had 100% and 70% protection against homologous (serotype 7) or heterologous (serotype 1, 3) challenge with A. pleuropneumoniae, respectively. The A. pleuropneumoniae mutant strain HB04C- and the counterselection method used in the study show promise in developing effective live vaccines for porcine pleuropneumonia and for other infections diseases of the respiratory system. © 2004 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved.
Bei, W., He, Q., Yan, L., Fang, L., Tan, Y., Xiao, S., … Chen, H. (2005). Construction and characterization of a live, attenuated apxIICA inactivation mutant of Actinobacillus pleuropneumoniae lacking a drug resistance marker. FEMS Microbiology Letters, 243(1), 21–27. https://doi.org/10.1016/j.femsle.2004.11.033